Main Conference Day 3 - PT (Pacific Time, GMT-08:00)
Main Conference Day 3
- PT (Pacific Time, GMT-08:00)
6:30am - 7:15am45 mins
Sunrise Yoga: Wellness Event - Rancho Santa Fe, Lobby Level
7:15am - 7:30am15 mins
Registration
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #1
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #2
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
8:10am - 8:15am5 mins
Track 1: Innovative Engineering for Cell Engagers
Co-Chairs’ Remarks - Innovative Engineering for Cell Engagers
- Paul Parren, PhD - Founder and CSO, Gyes BV
- Mitchell Ho, PhD - Senior Investigator, Laboratory of Molecular Biology, NIH NCI
8:10am - 8:15am5 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Co-Chairs’ Remarks - Antibody Drug Conjugates - Novel Payloads and Engineering
- Pamela Holland, PhD - Senior Vice President, Biology, InduPro
- Gail Lewis, PhD - Distinguished Scientist, Discovery Oncology, Genentech
8:15am - 8:45am30 mins
Track 1: Innovative Engineering for Cell Engagers
Protein-Engineering Strategies for Bispecific T-cell Engagers
- Yvonne Chen - Professor, University of California, Los Angeles
8:15am - 8:45am30 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Development of Site-Specific, High-DAR Dual-Payload ADCs
- Daniel Calarese, PhD - Executive Director of Research Innovation, Sutro Biopharma
8:45am - 9:15am30 mins
Track 1: Innovative Engineering for Cell Engagers
Discovery of Novel Selective Targets for T cell Engagers
- Dan Rock, PhD - Chief Scientific Officer, Cartography Biosciences
8:45am - 9:15am30 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Expanding the Reach of Targeted Cancer Therapy Using Multispecific Peptide-Drug Conjugates
- Caitlyn Miller - Researcher, Stanford University
9:15am - 9:45am30 mins
Track 1: Innovative Engineering for Cell Engagers
AI-driven Design of Gated Cell Engagers
- Peyton Greenside, Ph.D. - Chief Scientific Officer and Co-founder, BigHat Biosciences
9:15am - 9:45am30 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Precision Meets Power: Antibody-Drug Conjugates to Potentiate Radiotherapy in Solid Tumors
- Vaishali Kapoor - Assistant Professor, Radiation Oncology, Washington University School of Medicine
9:45am - 10:30am45 mins
Track 1: Innovative Engineering for Cell Engagers
Networking Refreshment Break, Exhibit and Poster Viewing
9:45am - 10:30am45 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Networking Refreshment Break, Exhibit and Poster Viewing
10:30am - 11:00am30 mins
Track 1: Innovative Engineering for Cell Engagers
Conditional Protein Therapeutics using Dual-Binding Antibodies
- Diane Hollenbaugh, PhD - Chief Scientific Officer, Bonum Therapeutics
10:30am - 11:00am30 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Exploring Targeted, Non-pan-cytotoxic ADC Payloads Across Different Targets for Efficacy and Enhanced TI
- Gail Lewis, PhD - Distinguished Scientist, Discovery Oncology, Genentech
11:00am - 11:30am30 mins
Track 1: Innovative Engineering for Cell Engagers
A PD-1-Targeted, Receptor-Masked Wild Type IL-2 with Improved Therapeutic Window for Cancer Immunotherapy
- Eric Smith - Executive Director - Bispecifics, Regeneron Pharmaceuticals
11:00am - 11:30am30 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
Dual Payload ADCs
- Marco Lobba, PhD - CEO & Co-Founder, CatenaBio
11:30am - 12:00pm30 mins
Track 1: Innovative Engineering for Cell Engagers
T-cell Engagers that Stabilize Drug-modified KRAS(G12C) Neoantigens Enable Selective and Potent Cross-HLA Immunotherapy
- Christoph Rader - Chief Technology Officer, Aethon Therapeutics
11:30am - 12:00pm30 mins
Track 2: Antibody Drug Conjugates - Novel Payloads and Engineering
ADC Development Update
- Sharsti Sandall, PhD - Executive Director, ADC Biology, Pfizer
12:00pm - 12:30pm30 mins
Scientific Briefing 1
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
12:00pm - 12:30pm30 mins
Scientific Briefing 2
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
12:00pm - 12:30pm30 mins
Scientific Briefing 3
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
12:00pm - 12:30pm30 mins
Scientific Briefing 4
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
12:00pm - 12:30pm30 mins
Scientific Briefing 5
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
12:30pm - 2:10pm100 mins
Networking Luncheon, Last Chance for Exhibit and Poster Viewing
2:10pm - 2:15pm5 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Co-Chairs' Remarks - Emerging In Vitro Approaches to Antibody Discovery
- Brandon DeKosky, Ph.D. - Associate Professor of Chemical Engineering, MIT and The Ragon Institute
- Jamie Spangler, PhD - Associate Professor, Johns Hopkins University
2:10pm - 2:15pm5 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Co-Chairs’ Remarks - Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
- James Larrick, MD, PhD - Managing Director and Chief Medical Officer , Panorama Research Institute
- Vaughn Smider, MD, PhD - President, The Applied Biomedical Science Institute
2:15pm - 2:45pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
OrthoRep-driven Antibody Evolution
- Chang Liu, PhD - Professor and Chancellor's Fellow, Biomedical Engineering, UC Irvine
2:15pm - 2:45pm30 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Kv1.3 Regulation of Innate Immunity
- Vaughn Smider, MD, PhD - President, The Applied Biomedical Science Institute
2:45pm - 3:15pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
RASP: Rapid Antiviral Screening Using hyperPhage Display
- Manpreet Kaur, PhD - Staff Scientist, Dept of Microbiology & Immunology, Albert Einstein College of Medicine
2:45pm - 3:15pm30 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Bispecific T-cell Engaging Antibodies to Ameliorate Fibrosis
- Kory Lavine, PhD - Professor of Internal Medicine, WashU Medicine
3:15pm - 3:45pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
De Novo Design of Hundreds of Functional GPCR-targeting Antibodies
- Surge Biswas, PhD - Co-founder & CEO, Nabla Bio
3:15pm - 3:45pm30 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Higher Order Receptor Clustering Due to the IgG3 Subclass is Necessary for TLR4 Signaling and Tolerance Induction by Novel Human anti-TLR4 Antibodies
- Luke Heuer, Ph.D. - Postdoctoral Researcher, University of California, Davis
3:45pm - 4:15pm30 mins
Networking Refreshment Break
4:15pm - 4:45pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Transforming Therapeutic Protein Engineering with Generative Biology
- M. Jack Borrok, PhD - Director, Protein Therapeutics, Rare Disease, Amgen
4:15pm - 4:45pm30 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Towards Bispecific Biologics to Treat Interstitial Lung Disease
- Gerlinde Wernig, PhD - Associate Professor, Stanford Medicine
4:45pm - 5:15pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Computational-driven Bispecifc Discovery
- Dima Kozakov, PhD - Professor, Stony Brook University
4:45pm - 5:15pm30 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Bispecific Antibody Shuttles for CNS Delivery of Biologics: Emerging Applications in Protein Delivery
- Peter Tessier, PhD - Albert M. Mattocks Professor, Departments of Pharmaceutical Sciences, Chemical Engineering and Biomedical Engineering, University of Michigan
5:15pm - 5:45pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Results of the AIntibody Competition
- Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
5:15pm - 5:45pm30 mins
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Development of Therapeutic Antibodies Modulating NPR1 Activity for Cardiovascular Diseases
- Jee Kim, PhD - Executive Director of Therapeutic, Regeneron Pharmaceuticals
On Demand
Track 2: Antibody Therapeutics in Emerging Disease Areas: Non-Oncology
Anti-PROX1 Regenerative Therapy for Retinal Diseases
- Jin Woo Kim, PhD - Professor, Department of Biological Sciences, KAIST
5:50pm - 5:55pm5 mins
Close of Conference
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。